BioNTech Authorizes $1 Billion Buyback as Shareholders Approve Cancer Focus Strategy
Published on 05/16/2026 at 06:03 | Redaktion boerse-global.de
BioNTech’s shareholders gave the green light to a sweeping corporate overhaul at Friday’s virtual annual meeting, endorsing an expanded supervisory board, a €129 million capital mandate, and a $1 billion share buyback program. The decisive votes — backed by 92% of the voting capital — signal investor confidence in the company’s transition from pandemic-era vaccine revenues to an oncology powerhouse, even as the stock trades well below its long-term averages.
The buyback authorization, valid until May 6, 2027, allows BioNTech to repurchase up to $1 billion of its American depositary shares. That move, paired with the approval of a new capital mandate covering up to half of the current share capital, gives management flexibility to return cash while funding the expensive pivot into cancer drug development.
Board Gets an Oncology Makeover
The supervisory board is expanding from six to eight members, a move designed to add deep clinical and commercial expertise. Newly elected directors Prof. Iris Löw-Friedrich and Susanne Schaffert bring backgrounds in clinical development, oncology, and drug marketing. Meanwhile, Helmut Jeggle remains on the board and was appointed chairman, joined by re-elected members Prof. Anja Morawietz and Prof. Rudolf Staudigl.
The reshuffle comes as founders Prof. U?ur ?ahin and Prof. Özlem Türeci prepare to depart at year-end. Chairman Jeggle took the opportunity to clarify that all patents, brands, and technology platforms belong to the group, not the founders personally. Chief Operating Officer Sierk Pötting extended his contract through December 2027, and Kylie Jimenez joined as chief people officer in March to oversee the organizational transformation.
Should investors sell immediately? Or is it worth buying BioNTech?
Trimming the COVID Infrastructure
BioNTech’s cost-cutting campaign is gathering pace. The company plans to shutter several international sites and eliminate up to 1,860 positions by 2029, generating annual savings of roughly €500 million. Vaccine production is shifting further toward partner Pfizer, with no expected disruption to medicine supply. The streamlining clears runway for BioNTech to finance its next growth phase from existing resources.
For 2026, the group reiterates revenue guidance of €2.0 billion to €2.3 billion, though it warns of continued high research and selling expenses. The financial discipline reflects a company determined to avoid the boom-and-bust pattern that plagued some former COVID peers.
Pipeline Hits the Spotlight
The real test lies in the clinic. BioNTech now has more than 25 ongoing Phase 2 and Phase 3 trials, spanning 17 clinical programs and involving data from over 4,000 patients. The flagship candidate is pumitamig, a bispecific immune modulator that has shown activity across multiple tumor types. Later this month at the ASCO cancer conference, the company will present Phase 2 data on pumitamig in a lung cancer study that directly compares it against Merck’s blockbuster pembrolizumab.
A strong readout would validate the oncology strategy and potentially unlock revaluation. BioNTech aims to bring several cancer drugs to market by 2030. The company expects to have 15 Phase 3 studies running in total and has already launched five registration-enabling trials with partner Bristol Myers Squibb for pumitamig alone.
Stock Sags as Analysts Diverge
Despite the governance overhaul and pipeline progress, the equity remains under pressure. Shares closed Friday at €76.95, down 2.22%, and have fallen 8.01% over the past 30 days. The stock now trades below its 200-day moving average by roughly 11%.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Analyst opinions are sharply divided. Canaccord cut its price target to $158 from $171, while Morgan Stanley edged its target up to $126. TD Cowen stands well below the pack at $94. Berenberg recently trimmed its target but still calls the stock “strongly undervalued.” Of 19 analysts covering BioNTech, 15 rate it a strong buy and four a hold, with targets spanning from $94 to $171. The wide range underscores how much the valuation hinges on upcoming clinical data.
Tax Structure Supports the Transition
Shareholders also approved a domineering and profit transfer agreement for BioNTech Discovery GmbH, a subsidiary that houses much of the research spending. The restructuring allows the group to offset the subsidiary’s profits against the parent’s losses, improving tax efficiency during this high-investment phase.
With the AGM formalities out of the way, all eyes turn to the end of May. The ASCO abstracts on pumitamig will offer the first major external read on whether BioNTech’s bet on cancer — and the painful downsizing that accompanies it — can deliver the clinical evidence the market demands.
Ad
BioNTech Stock: New Analysis - 16 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
